Inside the Beltway: Support for LDT discussion draft broad, but FDA wary of deadlines Nov. 20, 2015 By Mark McCarty
Targeting the microbiome: Nutritional value of food depends critically on the gut of the eater Nov. 20, 2015 By Anette Breindl
Domestic Products have edge: Chinese firms encouraged to pursue international investment opportunities Nov. 20, 2015 By Cornelia Zou
Old drug performing new tricks: Genentech explores new delivery for longstanding wet AMD drug Nov. 20, 2015 By Amanda Pedersen
IPO floodgates open: Success of JOBS Act leading to higher IPO costs for biotechs Nov. 20, 2015 By Mari Serebrov
SCS Teeming with Competition: St. Jude earns FDA nod for Proclaim, looks to gain ground within SCS market Nov. 20, 2015 By Omar Ford With an FDA approval of its Proclaim elite spinal cord stimulation (SCS) system in hand, St. Jude Medical Inc. (St. Paul, Minn.) could find itself poised to take a greater share of the SCS market. Read More
RSS